G1 Therapeutics Inc (OQ:GTHX)

Apr 17, 2024 09:00 am ET
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday May 1, 2024, at 8:30 a.m. ET. To register...
Apr 04, 2024 10:30 am ET
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23rd Annual Needham Virtual Healthcare Conference on Thursday,...
Apr 01, 2024 04:20 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 3,000 shares of G1’s common stock and 1,500 restricted stock units (RSUs) to one hired employee under...
Mar 01, 2024 04:20 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,100 shares of G1’s common stock and 1,050 restricted stock units (RSUs) to one hired employee under...
Feb 28, 2024 06:30 am ET
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the fourth quarter and full year ended December 31, 2023. “The strong fourth quarter 2023 vial volume growth of...
Feb 27, 2024 08:30 am ET
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in a Breast & Lung Cancer Corporate Panel Discussion during the TD Cowen 44th Annual Health...
Feb 15, 2024 08:30 am ET
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the fourth quarter and full year 2023 on Wednesday February 28, 2024, at 8:30 a.m....
Feb 12, 2024 04:05 pm ET
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the independent Data Monitoring Committee (DMC) recommended continuation of the pivotal Phase 3 trial (PRESERVE 2), evaluating trilaciclib in...
Jan 08, 2024 06:45 am ET
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced new clinical, commercial and corporate updates, including encouraging preliminary overall survival (OS) data from the Company’s ongoing Phase 2 trial of...
Jan 03, 2024 09:00 am ET
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 42nd Annual J.P. Morgan Healthcare Conference on January 10,...
Jan 02, 2024 04:51 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,300 shares of G1’s common stock and 3,000 restricted stock units (RSUs) to three hired employees...
Dec 05, 2023 09:26 am ET
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the presentation of new data describing the long-term positive survival impact of previous...
Dec 01, 2023 04:27 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 4,700 shares of G1’s common stock and 2,300 restricted stock units (RSUs) to one hired employee under...
Nov 29, 2023 08:37 pm ET
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that an abstract exploring the long-term impact of trilaciclib on survival outcomes in patients with metastatic triple negative breast cancer (mTNBC) from...
Nov 01, 2023 06:30 am ET
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the third quarter ended September 30, 2023. “Despite the impact of the ongoing platinum-based chemotherapy shortage, we...
Oct 27, 2023 07:00 am ET
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the presentation of four posters that provide new-real world evidence indicating that trilaciclib administered prior to platinum-based chemotherapy in...
Oct 18, 2023 08:00 am ET
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that COSELA® (trilaciclib) has been recommended as a myeloid supportive agent in the updated American Society of Clinical Oncology (ASCO) small cell lung...
Oct 18, 2023 07:30 am ET
G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the third quarter 2023 on Wednesday November 1, 2023, at 8:30 a.m. ET. Please note...
Oct 16, 2023 09:00 am ET
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that multiple abstracts have been accepted for poster presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium,...
Sep 18, 2023 07:00 am ET
Black Diamond Therapeutics Announces CEO Transition
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, announced that current Chairman of the...
Sep 05, 2023 11:00 am ET
G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Communications Officer Will Roberts will provide a corporate presentation on September 12, 2023, at 9:30 AM EDT during the H.C. Wainwright 25th...
Sep 01, 2023 04:15 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,800 shares of G1’s common stock and 3,300 restricted stock units (RSUs) to two hired employees under...
Aug 02, 2023 06:30 am ET
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
Provided Phase 2 Mechanism of Action Trial Results Clarifying Trilaciclib's Role in Enhancing Immune Surveillance and Efficacy as Measured by Long Term Endpoints like Overall Survival (OS) - - Improved Financial Strength By Amending Hercules Debt...
Jul 31, 2023 02:30 pm ET
G1 Therapeutics to Participate in Two August Investor Conferences
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will participate in two August investor conferences. On Monday August 7, 2023, G1’s Chief Executive Officer Jack Bailey and other members of G1’s...
Jul 31, 2023 08:30 am ET
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the publication of real world outcomes data from published and new unpublished studies showing the potential of trilaciclib to reduce single and multilineage...
Jul 26, 2023 09:00 am ET
G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the second quarter 2023 on Wednesday August 2, 2023, at 8:30 a.m. ET. Please...
Jul 06, 2023 04:15 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 5,600 shares of G1’s common stock and 2,800 restricted stock units (RSUs) to two hired employees under...
Jun 04, 2023 07:13 am ET
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from 24 patients enrolled in its Phase 2, single arm mechanism of action study of trilaciclib administered as a single agent to patients with...
Jun 01, 2023 04:40 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,300 shares of G1’s common stock and 3,000 restricted stock units (RSUs) to three hired employees...
May 22, 2023 04:45 pm ET
G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Monica Thomas as its General Counsel and Chief Compliance Officer. Mrs. Thomas replaces Stillman Hanson who departed the Company in May...
May 16, 2023 07:30 am ET
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today described recently presented real-world data that confirm a consistent risk of myelosuppressive events (neutropenia, anemia, thrombocytopenia) across patients with...
May 10, 2023 07:31 am ET
New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented preliminary results from 30 patients enrolled in its ongoing Phase 2, single arm study of trilaciclib administered prior to the antibody-drug conjugate...
May 03, 2023 06:30 am ET
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the first quarter ended March 31, 2023. “Since the start of 2023, we've focused efforts on our three core priorities of...
May 01, 2023 05:00 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 4,200 shares of G1’s common stock and 2,000 restricted stock units (RSUs) to two hired employees under...
Apr 26, 2023 12:45 pm ET
G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter 2023 on Wednesday May 3, 2023, at 8:30 a.m. ET. Please note that...
Apr 11, 2023 12:30 pm ET
G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey and other members of the Executive Team will participate in a fireside chat during the 22nd Annual Needham...
Mar 01, 2023 06:30 am ET
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
- Achieved $31.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2022, Representing 182% Growth Over 2021; Provided 2023 Net COSELA Revenue Guidance of $50 to $60 Million -
Feb 28, 2023 02:10 pm ET
G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on March 7th, 2023, at 10:30 AM EST, G1’s Chief Executive Officer Jack Bailey will participate in the moderated Breast and Lung Cancer Panel during the...
Feb 22, 2023 10:00 am ET
G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year 2022 on Wednesday, March 1, 2023, at 8:30 a.m. ET....
Feb 13, 2023 06:00 am ET
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced topline results from its pivotal Phase 3 PRESERVE 1 trial showing that the trial achieved its co-primary endpoints related to severe neutropenia with...
Feb 09, 2023 07:00 am ET
First Prescription for COSELA® (trilaciclib) Issued in China
- COSELA®, the world's first and only myeloprotection drug, was prescribed in Jilin Cancer Hospital on January 28, 2023
Feb 01, 2023 04:46 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,800 shares of G1’s common stock and 1,400 restricted stock units (RSUs) to one hired employee under...
Jan 11, 2023 07:00 am ET
G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 19th, 2023, at 11:30 AM EST, G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the virtual 2023 B. Riley...
Jan 09, 2023 06:30 am ET
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
Trilaciclib’s Potential Synergistic Effects with Chemotherapy, Antibody Drug Conjugates (ADCs), and Checkpoint Inhibitors Are Being Evaluated - RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX),...
Jan 04, 2023 06:30 am ET
G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided an initial update on PRESERVE 3, an ongoing Phase 2, randomized, open-label study of first-line platinum-based chemotherapy and maintenance therapy with the...
Jan 03, 2023 02:00 pm ET
G1 Therapeutics to Participate in the 41st Annual J.P. Morgan Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 11, 2023, at 1:30 PM PST, G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 41st Annual J.P. Morgan...
Dec 07, 2022 06:04 pm ET
Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided initial results from a 24 patient Phase 2 mechanism of action (MOA) trial showing favorable alterations in the tumor microenvironment from a single dose of...
Dec 01, 2022 11:41 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 14,400 shares of G1’s common stock and 9,400 restricted stock units (RSUs) to five hired employees...
Nov 23, 2022 10:30 am ET
G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive Officer, and other members of the executive team will participate virtually in the Evercore ISI HealthCONx Conference....
Nov 22, 2022 04:01 pm ET
G1 Therapeutics Announces Closing of Offering of Common Stock
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the closing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share. G1...
Nov 17, 2022 08:12 pm ET
G1 Therapeutics Announces Pricing of Offering of Common Stock
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the pricing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share, for total gross...
Nov 17, 2022 04:01 pm ET
G1 Therapeutics Announces Proposed Public Offering of Common Stock
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it has commenced an underwritten public offering of its common stock. All of the shares in the offering will be sold by G1 Therapeutics. In addition, G1...
Nov 02, 2022 06:30 am ET
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
- Achieved $23.6 million in Total Revenue in the Third Quarter of 2022 Including $8.3 million in Net Revenue from Sales of COSELA® (trilaciclib) -
Nov 02, 2022 06:28 am ET
Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today described safety data from the first 18 patients enrolled in its ongoing Phase 2, single arm study of trilaciclib administered prior to the antibody-drug conjugate...
Nov 01, 2022 05:40 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 5,200 shares of G1’s common stock and 3,400 restricted stock units (RSUs) to one hired employee under...
Oct 26, 2022 09:26 am ET
G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it is supporting a Phase 2 investigator initiated study (ISS) of trilaciclib and lurbinectedin in patients with extensive stage small cell lung cancer...
Oct 19, 2022 12:30 pm ET
G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2022 on Wednesday, November 2, 2022, at 8:30 a.m. ET. Please...
Oct 10, 2022 06:30 am ET
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized in PRESERVE 2, G1’s Phase 3 clinical trial of trilaciclib in patients with metastatic triple negative breast cancer...
Oct 03, 2022 05:00 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 44,300 shares of G1’s common stock and 29,400 restricted stock units (RSUs) to three hired employees...
Sep 07, 2022 08:00 am ET
G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive Officer, and other members of the executive team will participate virtually in the H.C. Wainwright 24th Annual Global...
Sep 06, 2022 07:00 am ET
G1 Therapeutics to Host Virtual R&D Day on September 15, 2022
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will host a virtual R&D Day, “Innovations in Oncology: The Science of Trilaciclib”, on Thursday, September 15, 2022, from 9:00 a.m. to 11:00...
Sep 01, 2022 05:22 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 10,000 shares of G1’s common stock and 6,600 restricted stock units (RSUs) to one hired employee under...
Aug 03, 2022 06:30 am ET
G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights
Completed Patient Enrollment in Phase 2 Mechanism of Action Trial of Trilaciclib in Neoadjuvant Triple Negative Breast Cancer (TNBC) - - Achieved Target Enrollment in Phase 2 Trial of Trilaciclib in Bladder Cancer (mUC) (PRESERVE 3) - - Announced...
Aug 01, 2022 05:15 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 10,800 shares of G1’s common stock and 7,200 restricted stock units (RSUs) to two hired employees under...
Aug 01, 2022 09:00 am ET
G1 Therapeutics to Participate Virtually in the 2022 BTIG Biotechnology Conference and the 2022 Wedbush Pacgrow Healthcare Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in August 2022. On Tuesday August 9, 2022, G1’s Chief Executive Officer Jack...
Jul 25, 2022 06:30 am ET
G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Norman E. “Ned” Sharpless, M.D., to its Board of Directors. For nearly 30 years, Dr. Sharpless has been committed to the fight against...
Jul 20, 2022 09:00 am ET
G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2022 on Wednesday, August 3, 2022, at 8:30 a.m. ET. Please...
Jul 13, 2022 10:15 am ET
COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-S
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the China National Medical Products Administration (NMPA) has conditionally approved COSELA (trilaciclib hydrochloride for injection), which was jointly...
Jul 01, 2022 05:20 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 40,400 shares of G1’s common stock and 26,800 restricted stock units (RSUs) to six hired employees...
Jun 28, 2022 07:30 am ET
G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board of Directors. For more than 30 years, Mr. Lee has developed extensive experience in manufacturing and supply chain...
Jun 13, 2022 07:00 am ET
G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized in the Phase 3 clinical trial of trilaciclib for patients with metastatic colorectal cancer (mCRC) receiving...
Jun 02, 2022 11:00 am ET
Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patie
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results of a post-hoc study analysis showing that ES-SCLC patients who received trilaciclib prior to chemotherapy had a lower incidence of single- and...
Jun 01, 2022 04:45 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 1,400 shares of G1’s common stock and 800 restricted stock units (RSUs) to one hired employee under the...
May 20, 2022 10:30 am ET
G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business Journal
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it received Triangle Business Journal's 2022 Company of the Year (Public) award, one of two such awards presented at the 2022 Life Sciences Award...
May 18, 2022 10:15 am ET
G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive Officer, will provide a virtual corporate presentation during the H.C. Wainwright & Co. Global Investment Conference....
May 04, 2022 06:30 am ET
G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights
Fully Deployed G1’s COSELA Sales Team as of Mid-February 2022 - - Confirmed Expected Timelines for Initial Results of Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib - - Presented Real-World Data Showing Impact of Trilaciclib...
May 02, 2022 05:30 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 63,500 shares of G1’s common stock and an aggregate of 38,000 restricted stock units...
Apr 21, 2022 08:30 am ET
G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2022 on Wednesday, May 4, 2022 at 8:30 a.m. ET. The live call...
Apr 06, 2022 11:30 am ET
G1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey and Raj Malik, M.D., G1’s Chief Executive Officer and Chief Medical Officer, respectively, will participate in a fireside chat during the...
Apr 01, 2022 04:15 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 25,800 shares of G1’s common stock and an aggregate of 11,200 restricted stock units...
Mar 31, 2022 04:05 pm ET
New Real-World Data Show Potential of Trilaciclib to Reduce the Substantial Burden of Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Chemotherapy
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results of a retrospective, observational study describing the substantial burden of myelosuppression and its impact on healthcare resource utilization...
Mar 01, 2022 05:00 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 10,800 shares of G1’s common stock and an aggregate of 8,800 restricted stock units...
Mar 01, 2022 11:15 am ET
G1 Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference and the 34th Annual Roth 2022 Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming investor conferences in March 2022. On Tuesday March 8, 2022, G1’s Chief Executive Officer Jack Bailey...
Feb 23, 2022 06:30 am ET
G1 Therapeutics Provides Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
Completed Hiring, Training, and Deployment of G1’s COSELA Sales Team - - Announced That Initial Results from Phase 3 Trial of Trilaciclib in Colorectal Cancer (PRESERVE 1) Are Now Expected Early in the First Quarter of 2023 - - Initiated Two New...
Feb 09, 2022 09:15 am ET
G1 Therapeutics to Provide Fourth Quarter and Full Year 2021 Financial Results and Business Update on February 23, 2022
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year 2021 on Wednesday, February 23, 2022 at 8:30 a.m....
Feb 01, 2022 05:30 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 166,700 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc....
Jan 04, 2022 09:15 am ET
G1 Therapeutics to Participate in the 40th Annual J.P. Morgan and H.C. Wainwright BioConnect Virtual Conferences in January 2022
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in January. G1’s Chief Executive Officer Jack Bailey and Chief Medical...
Jan 03, 2022 05:30 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of G1’s common stock to three employees under the G1 Therapeutics, Inc....
Dec 16, 2021 06:00 am ET
G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will hire and deploy an additional 20 salespeople, bringing the total number of oncology sales representatives to 34. The expansion will...
Dec 01, 2021 06:20 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 101,700 shares of G1’s common stock to seven employees under the G1 Therapeutics, Inc....
Dec 01, 2021 07:00 am ET
G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor Microenvironment
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated a Phase 2, single arm, open-label study of trilaciclib in patients with early-stage triple negative breast cancer (TNBC)...
Nov 29, 2021 07:00 am ET
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated a Phase 2, single arm, open-label study of trilaciclib administered prior to the antibody-drug conjugate (ADC), Trodelvy®...
Nov 12, 2021 08:25 am ET
Immune Analysis from Phase 2 Triple Negative Breast Cancer Trial Demonstrates Trilaciclib Enhanced Patients’ T Cell Immune Function When Administered Prior to Chemotherapy
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results from an immunologic analysis of Phase 2 study data showing that trilaciclib enhances both CD4 and CD8 T cell function in certain patients with...
Nov 10, 2021 11:40 am ET
G1 Therapeutics to Participate in Two Upcoming Conferences
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences. On November 17, 2021 at 8:00 AM EST, G1’s Chief Executive Officer Jack...
Nov 03, 2021 06:30 am ET
G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights
Announced Supplemental COSELA Sales Force to Target Top Tier Accounts and Publication of Permanent J-Code for COSELA - - Initiation of Two New Phase 2 Trials Expected in the Fourth Quarter of 2021 to Further Investigate Trilaciclib’s Immune-Based...
Nov 01, 2021 06:00 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 13,000 shares of G1’s common stock to one employee under the G1 Therapeutics, Inc. 2021...
Oct 20, 2021 08:00 am ET
G1 Therapeutics to Provide Third Quarter 2021 Financial Results and Business Update on November 3, 2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2021 on Wednesday, November 3, 2021 at 8:30 a.m. ET. The live...
Oct 15, 2021 09:31 am ET
Thinking about buying stock in Limelight Networks, G1 Therapeutics, Allegheny Technologies, Marathon Digital, or Nextplay Technologies?
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LLNW, GTHX, ATI, MARA, and NXTP.
Oct 07, 2021 08:00 am ET
Retrospective Analysis of Pooled Results from Three Studies Shows COSELA™ (Trilaciclib) Reduced Use of Supportive Care Interventions in Extensive Stage Small Cell Lung Cancer Patients Who Receive the
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results from a retrospective analysis of the pooled results of three randomized trilaciclib studies showing that patients with extensive-stage small-cell...
Oct 01, 2021 04:30 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 62,100 shares of G1’s common stock to six employees under the G1 Therapeutics, Inc....
Oct 01, 2021 07:45 am ET
G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid Services
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the permanent J-code for COSELA™ (trilaciclib) that was issued in July 2021 by the Centers for Medicare & Medicaid Services (CMS) is now effective for...
Sep 15, 2021 06:45 am ET
G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will hire and train a 15-person oncology sales force to supplement the Boehringer Ingelheim oncology commercial team. The expansion will allow G1 to...
Sep 03, 2021 07:45 am ET
G1 Therapeutics to Participate in Two Upcoming September Conferences
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in September. On September 10, 2021, G1 will participate in the Citi 16th...
Sep 03, 2021 07:30 am ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 43,400 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc....
Aug 04, 2021 04:01 pm ET
G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights
Initiated Pivotal Phase 3 Trial in Metastatic Triple-Negative Breast Cancer (TNBC) Evaluating the Survival Benefit of COSELA Compared with Placebo - - Initiated Randomized Phase 2 Studies of COSELA in Non-Small Cell Lung Cancer (NSCLC) and Bladder...
Aug 04, 2021 08:00 am ET
G1 Therapeutics Granted New Technology Add-On Payment (NTAP) for COSELA™ (Trilaciclib) by Centers for Medicare & Medicaid Services (CMS)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for COSELA™ (trilaciclib) when administered to...
Aug 02, 2021 06:50 am ET
G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Andrew Perry as its Chief Commercial Officer (CCO). Mr. Perry replaces Soma Gupta who has left the Company for personal and professional...
Jul 28, 2021 08:00 am ET
G1 Therapeutics to Provide Second Quarter 2021 Financial Results and Business Update on August 4, 2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 4, 2021 at 4:30 p.m. ET. The live...
Jul 19, 2021 09:20 am ET
G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Tr
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to COSELA™ (trilaciclib) investigation for use in combination with...
Jul 15, 2021 04:05 pm ET
Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced the appointment of Jennifer Moses, CPA to the...
Jul 02, 2021 07:30 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 80,400 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc....
Jun 18, 2021 09:00 am ET
G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Alicia Secor to its Board of Directors. With more than 30 years of experience in the life sciences industry, she has a proven track record...
Jun 16, 2021 07:00 am ET
G1 Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in the 2021 Raymond James Human Health Innovation Conference. The fireside chat will take...
Jun 14, 2021 07:00 am ET
G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated PRESERVE 3, a Phase 2, randomized, open-label study of COSELA™ (trilaciclib) administered with first-line platinum-based...
Jun 04, 2021 04:01 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 44,200 shares of G1’s common stock to five employees under the G1 Therapeutics, Inc....
Jun 04, 2021 09:02 am ET
G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Brea
60% Clinical Benefit Rate Achieved in Full Analysis Set at Week 24 - RESEARCH TRIANGLE PARK, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from its...
Jun 04, 2021 09:01 am ET
G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from analyses evaluating the immune effects of trilaciclib in patients with extensive-stage small cell lung cancer (ES-SCLC) following two Phase 2...
May 19, 2021 05:01 pm ET
G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, being held virtually June 4th through 8th. The presentations...
May 17, 2021 07:00 am ET
G1 Therapeutics Presents Two Posters at ISPOR Describing the Estimated Economic Impact of Treating Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented two scientific posters at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) describing the estimated economic impact of treating...
May 10, 2021 06:50 am ET
G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated PRESERVE 4, a multicenter randomized, double blind, placebo controlled Phase 2 study of COSELA™ (trilaciclib) administered...
May 07, 2021 04:01 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 40,000 shares of G1’s common stock to five employees under the G1 Therapeutics, Inc....
May 05, 2021 04:01 pm ET
G1 Therapeutics Provides First Quarter 2021 Financial Results and Operational Highlights
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the first quarter ended March 31, 2021. “The first quarter of 2021 was a transformational period for G1 as the...
Apr 28, 2021 10:00 am ET
G1 Therapeutics to Provide First Quarter 2021 Financial Results and Business Update on May 5, 2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2021 on Wednesday, May 5, 2021 at 4:30 p.m. ET. The live call...
Apr 28, 2021 07:00 am ET
G1 Therapeutics Announces Initiation of Phase 3 Registrational Study of COSELA™ (trilaciclib) in Triple-Negative Breast Cancer (TNBC)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the initiation of PRESERVE 2, a pivotal Phase 3, randomized, double-blind, placebo-controlled study of COSELA™ (trilaciclib) in patients receiving first- or...
Apr 26, 2021 09:41 am ET
G1 Therapeutics Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the peer-reviewed journal of Clinical Lung Cancer has published the final pooled results from three clinical trials of COSELA™ (trilaciclib) in...
Apr 07, 2021 07:00 am ET
G1 Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in the 20th Annual Needham Virtual Healthcare Conference. The fireside chat will take place on...
Apr 02, 2021 04:05 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 46,300 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc....
Apr 01, 2021 07:30 am ET
G1 Therapeutics to Host Virtual COSELA™ (trilaciclib) Kickoff Analyst and Investor Summit on April 9, 2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will host a virtual COSELA Kickoff Analyst and Investor Summit on Friday, April 9, 2021 from 9:00 a.m. to 11:00 a.m. EDT. G1 Therapeutics...
Mar 25, 2021 06:50 am ET
G1 Therapeutics’ COSELA™ (trilaciclib) Included in Two Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that COSELA™ (trilaciclib) has been added to two updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN...
Mar 05, 2021 04:05 pm ET
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 14,300 shares of G1’s common stock to two employees under the G1 Therapeutics, Inc....
Mar 03, 2021 07:30 am ET
G1 Therapeutics to Participate in Two Investor Conferences in March
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two investor conferences in March. Jack Bailey, G1’s Chief Executive Officer, will provide a presentation during the HC...
Mar 02, 2021 06:59 am ET
G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy
G1 Therapeutics, Inc. (Nasdaq: GTHX) and Boehringer Ingelheim today announced that COSELA™ (trilaciclib) for injection is now available in the U.S. On February 12, 2021, the U.S. Food and Drug Administration (FDA) approved COSELA to decrease the...
Feb 24, 2021 04:01 pm ET
G1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the fourth quarter and full-year ended December 31, 2020. “With the recent approval of COSELA, we have a tremendous...
Feb 17, 2021 08:00 am ET
G1 Therapeutics to Provide Fourth Quarter and Full Year 2020 Financial Results and Business Update on February 24, 2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year of 2020 on Wednesday, February 24, 2021 at 4:30 p.m....
Feb 16, 2021 07:31 am ET
Thinking about buying stock in G1 Therapeutics, Strongbridge Biopharma, Soligenix, Pieris Pharmaceuticals, or Diffusion Pharmaceuticals?
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GTHX, SBBP, SNGX, PIRS, and DFFN.
Feb 12, 2021 07:40 pm ET
FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved COSELA™ (trilaciclib) for injection to decrease the incidence of chemotherapy-induced...
Feb 04, 2021 07:30 am ET
G1 Therapeutics to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day Virtual Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in the Guggenheim Healthcare Talks: 2021 Oncology Day conference. The fireside chat will take...
Feb 02, 2021 08:31 am ET
Thinking about trading options or stock in Pfizer, Daqo New Energy, Horizon Therapeutics, Intel Corp, or G1 Therapeutics?
NEW YORK, Feb. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, DQ, HZNP, INTC, and GTHX.
Jan 26, 2021 03:22 pm ET
Glancy Prongay & Murray LLP Announces Investigation of G1 Therapeutics, Inc.
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of G1 Therapeutics, Inc. (Nasdaq: GTHX) concerning the Company and its directors’ and officers’ possible violations of state laws.
Jan 05, 2021 07:00 am ET
G1 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Bailey will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021 at 2:50 p.m....
Jan 04, 2021 07:00 am ET
G1 Therapeutics Announces Appointment of William C. Roberts as Vice President, Investor Relations & Corporate Communications
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointment of William C. Roberts as its Vice President, Investor Relations & Corporate...
Dec 09, 2020 05:00 pm ET
G1 Therapeutics Presents Final Phase 2 Clinical Data on Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Surviv
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported final data from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer (mTNBC) showing that trilaciclib significantly improved...
Nov 30, 2020 08:31 am ET
Thinking about trading options or stock in Tesla, G1 Therapeutics, Apple, Micron Technology, or At Home Group?
NEW YORK, Nov. 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, GTHX, AAPL, MU, and HOME.
Nov 24, 2020 07:00 am ET
G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that incoming Chief Executive Officer Jack Bailey and Chief Medical Officer and Senior Vice President, R&D Raj Malik, M.D. will present a company update at the...
Nov 18, 2020 07:00 am ET
G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that final overall survival (OS) data from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer (mTNBC) were consistent with...
Nov 11, 2020 07:01 am ET
G1 Therapeutics to Present at the Stifel Virtual Healthcare Conference on November 18, 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Bailey will present a company update at the Stifel 2020 Virtual Healthcare conference on November 18, 2020 at 11:20 a.m. ET....
Nov 04, 2020 04:01 pm ET
G1 Therapeutics Provides Third Quarter 2020 Corporate and Financial Update
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the third quarter ended September 30, 2020. “Since I joined G1 in 2014, the company has made tremendous progress in...
Oct 28, 2020 07:01 am ET
G1 Therapeutics to Provide Third Quarter 2020 Corporate and Financial Update on November 4, 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2020 on Wednesday, November 4, 2020 at...
Oct 15, 2020 07:00 am ET
G1 Therapeutics to Present Data on Trilaciclib at North America Conference on Lung Cancer (NACLC)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that four presentations highlighting the myelopreservation benefits of trilaciclib and its ability to reduce the need for reactive interventions will be...
Sep 30, 2020 04:01 pm ET
G1 Therapeutics Announces Chief Executive Officer Succession Plan
G1 Therapeutics, Inc. (Nasdaq: GTHX), a company whose mission is to deliver innovative therapies that improve the lives of people with cancer, today announced that effective January 1, 2021, Mark Velleca, M.D. Ph.D., will transition to the role of...
Sep 14, 2020 07:00 am ET
G1 Therapeutics to Present Data on Oral CDK4/6 Inhibitor Lerociclib at European Society for Medical Oncology (ESMO) Virtual 2020 Congress
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that two presentations highlighting data on the investigational oral CDK4/6 inhibitor lerociclib, including updated findings from a Phase 2 trial of lerociclib...
Sep 02, 2020 07:01 am ET
G1 Therapeutics to Participate in Four Investor Conferences in September 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will participate in the following investor conferences in September 2020: Citi 15th Annual BioPharma Virtual Conference: G1 will host...
Aug 17, 2020 06:00 am ET
G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for trilaciclib for small cell lung cancer (SCLC) patients being...
Aug 05, 2020 04:01 pm ET
G1 Therapeutics Provides Second Quarter 2020 Corporate and Financial Update
Co-promotion agreement with Boehringer Ingelheim for U.S. trilaciclib launch- Partnership for trilaciclib in China and global out-licensing of lerociclib net a combined $40 million in upfront payments, up to $486 million in milestone payments, plus...
Aug 04, 2020 07:00 am ET
G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present company updates at two investor conferences in August 2020: BTIG Virtual Biotechnology...
Aug 03, 2020 07:00 am ET
G1 Therapeutics and Simcere Announce Exclusive License Agreement for Trilaciclib in Greater China
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, and Simcere Pharmaceutical Group, a pharmaceutical company rapidly transitioning to an innovative and R&D-driven company in China, today announced an exclusive license...
Jul 29, 2020 07:01 am ET
G1 Therapeutics to Provide Second Quarter 2020 Corporate and Financial Update on August 5, 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2020 on Wednesday, August 5, 2020 at 5:00...
Jul 22, 2020 06:00 pm ET
G1 Therapeutics Announces License Agreement for Lerociclib
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced a license agreement for lerociclib to EQRx™, a biopharmaceutical company focused on making innovative medicines at dramatically lower prices for the benefit of...
Jun 30, 2020 04:10 pm ET
G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto Rico
G1 Therapeutics, Inc. (Nasdaq: GTHX) and Boehringer Ingelheim today announced that the companies have entered into a co-promotion agreement for trilaciclib in the United States and Puerto Rico. Under the terms of the three-year agreement, G1 and...
Jun 22, 2020 06:00 am ET
G1 Therapeutics and Genor Biopharma Announce Exclusive License Agreement for Lerociclib in Asia-Pacific Region
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, and Genor Biopharma Co. Inc., a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, today announced an...
Jun 01, 2020 04:01 pm ET
G1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules Capital
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $100 million. G1 plans to use the proceeds to...
May 13, 2020 05:31 pm ET
G1 Therapeutics to Present Data Showing Myelopreservation Benefits of Trilaciclib in Patients with Small Cell Lung Cancer at the ASCO20 Virtual Scientific Program
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that data across three randomized, double-blind, placebo-controlled Phase 2 trials of the investigational therapy trilaciclib in small cell lung cancer (SCLC)...
May 06, 2020 04:01 pm ET
G1 Therapeutics Provides First Quarter 2020 Corporate and Financial Update
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the first quarter ended March 31, 2020. “We have activated business continuity plans in response to the COVID-19 pandemic...
Apr 29, 2020 07:00 am ET
G1 Therapeutics to Provide First Quarter 2020 Corporate and Financial Update on May 6, 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2020 on Wednesday, May 6, 2020 at 4:30...
Apr 07, 2020 07:00 am ET
G1 Therapeutics to Present at 19th Annual Needham Virtual Healthcare Conference on April 14, 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company update at the 19th Annual Needham Virtual Healthcare Conference on April 14, 2020...
Mar 12, 2020 08:05 am ET
G1 Therapeutics Announces Appointment of New Board Member and Chief Commercial Officer
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointments of Jack Bailey to its Board of Directors and Soma Gupta as its Chief Commercial Officer (CCO). “We are pleased to welcome Jack and Soma,...
Feb 26, 2020 04:01 pm ET
G1 Therapeutics Provides Fourth Quarter and Full-Year 2019 Corporate and Financial Update
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the fourth quarter and full-year ended December 31, 2019. “We achieved significant clinical and regulatory milestones...
Feb 24, 2020 07:00 am ET
G1 Therapeutics to Present at Investor Conferences in March 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will present corporate updates at the following investor conferences in March 2020: Cowen & Company 40th Annual Healthcare Conference: Chief...
Feb 19, 2020 07:00 am ET
G1 Therapeutics to Provide Fourth Quarter and Full Year 2019 Corporate and Financial Update on February 26, 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year of 2019 on Wednesday, February...
Feb 18, 2020 07:00 am ET
G1 Therapeutics to Participate in BTIG Targeted Therapeutics Conference on February 24, 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Medical Officer Raj Malik, M.D., will participate in the “Breast Cancer – The Moving Landscape” panel discussion at the BTIG Targeted Therapeutics...
Feb 17, 2020 07:00 am ET
G1 Therapeutics to Participate in BTIG Targeted Therapeutics Conference on February 24, 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Medical Officer Raj Malik, M.D., will participate in the “Breast Cancer – The Moving Landscape” panel discussion at the BTIG Targeted Therapeutics...
Feb 06, 2020 07:00 am ET
G1 Therapeutics to Participate in Guggenheim Health Talks: Oncology Day on February 13, 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will participate in a fireside chat at the Guggenheim Healthcare Talks: Oncology Day. The fireside chat...
Jan 14, 2020 07:00 am ET
Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast Cancer
Quantum Leap Healthcare Collaborative™ (QLHC) and G1 Therapeutics, Inc. (Nasdaq: GTHX) announced today a collaboration to evaluate trilaciclib, an investigational therapy designed to improve outcomes for people with cancer treated with...
Jan 07, 2020 07:00 am ET
G1 Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference. The presentation...
Dec 11, 2019 06:00 pm ET
G1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported additional data from the Phase 1b/2a clinical trial investigating its oral CDK4/6 inhibitor lerociclib in combination with fulvestrant for the treatment of...
Nov 26, 2019 07:00 am ET
G1 Therapeutics to Participate in Evercore ISI 2nd Annual HealthCONx Conference on December 4, 2019
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference.  The fireside...
Nov 12, 2019 07:00 am ET
G1 Therapeutics to Present at Stifel Healthcare Conference on November 19, 2019
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the Stifel Healthcare Conference.  The presentation will take place...
Nov 05, 2019 04:00 pm ET
G1 Therapeutics Provides Third Quarter 2019 Corporate and Financial Update
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the third quarter ended September 30, 2019. “Based on written feedback from the FDA following our pre-NDA meeting in...
Oct 29, 2019 07:00 am ET
G1 Therapeutics to Provide Third Quarter Corporate and Financial Update on November 5, 2019
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2019 on Tuesday, November 5, 2019 at 4:30...
Sep 29, 2019 06:00 am ET
G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary results from a Phase 1/2a dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in patients with estrogen...
Sep 28, 2019 04:15 am ET
G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant I
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported preliminary overall survival (OS) data from the company’s randomized Phase 2 trial of trilaciclib in combination with chemotherapy for the treatment of...
Sep 10, 2019 06:01 am ET
G1 Therapeutics to Present New Clinical Data Across Pipeline at European Society for Medical Oncology (ESMO) 2019 Congress
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced new clinical data on trilaciclib, lerociclib and G1T48 will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress taking place...
Sep 03, 2019 07:00 am ET
G1 Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference on September 9, 2019
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Financial Officer Jennifer Moses will present a company overview at the H.C. Wainwright Annual Global Investment Conference.  The presentation will...
Aug 07, 2019 04:01 pm ET
G1 Therapeutics Provides Second Quarter 2019 Corporate and Financial Update
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the second quarter ended June 30, 2019. “Our most advanced investigational therapy, trilaciclib, has demonstrated...
Aug 06, 2019 07:00 am ET
G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will participate in two investor conferences in August 2019. The company will meet with investors at the 2019 BTIG Biotechnology Conference...
Jul 31, 2019 07:00 am ET
G1 Therapeutics to Provide Second Quarter Corporate and Financial Update on August 7, 2019
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2019 on Wednesday, August 7, 2019 at 4:30...
Jul 30, 2019 07:01 am ET
G1 Therapeutics Appoints Mark Avagliano as Chief Business Officer
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointment of Mark Avagliano as Chief Business Officer. In this role, Mr. Avagliano will serve as a member of the G1 executive team and be responsible for...
Jun 18, 2019 06:00 am ET
G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic T
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from a randomized Phase 2 trial which demonstrated that women with metastatic triple-negative breast cancer (mTNBC)...
Jun 14, 2019 07:01 am ET
G1 Therapeutics to Present Patient-Reported Outcomes (PRO) Data on Trilaciclib At Multinational Association of Supportive Care in Cancer (MASCC) And International Society of Oral Oncology (ISCOO) 2019
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that an analysis of patient-reported outcomes (PRO) data from three Phase 2 trials of trilaciclib in small cell lung cancer patients will be featured as an...
Jun 13, 2019 07:01 am ET
G1 Therapeutics Announces Updates to Board of Directors
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that current board member Garry Nicholson has been named as board chair, succeeding former chair Seth Rudnick, M.D. Dr. Rudnick, Sir Andrew Witty and Fredric...
Jun 11, 2019 07:00 am ET
G1 Therapeutics to Present at Raymond James Life Sciences and MedTech Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the Raymond James Life Sciences and MedTech Conference. The...
Jun 01, 2019 04:00 pm ET
G1 Therapeutics Presents Additional Phase 2 Data on Trilaciclib in Small Cell Lung Cancer at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
- New patient-reported outcomes data shows trilaciclib improves chemotherapy experience for patients - G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today presented additional findings from a randomized Phase 2 clinical...
May 16, 2019 07:00 am ET
G1 Therapeutics to Present Additional Trilaciclib Phase 2 Small Cell Lung Cancer Data at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that additional findings from a Phase 2 clinical trial demonstrating the myelopreservation benefits of trilaciclib in 2nd/3rd-line small cell lung cancer...
May 13, 2019 07:00 am ET
G1 Therapeutics to Present at UBS Global Healthcare Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the UBS Global Healthcare Conference. The presentation will take...
May 09, 2019 04:01 pm ET
G1 Therapeutics Provides First Quarter 2019 Corporate and Financial Update
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the first quarter ended March 31, 2019. “Following meetings with regulatory authorities, we have clarity on a path to...
May 02, 2019 07:00 am ET
G1 Therapeutics to Report First Quarter Financial Results on May 9, 2019
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to report financial results for the first quarter of 2019 on Thursday, May 9, 2019 at 4:30 p.m. ET. The live...
Apr 29, 2019 04:01 pm ET
G1 Therapeutics Announces Positive Feedback from Trilaciclib End-of-Phase 2 Meeting with FDA; Expects to File NDA in 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a regulatory update on trilaciclib, a first-in-class myelopreservation agent designed to protect the bone marrow from damage by chemotherapy and improve patient...
Apr 08, 2019 07:10 am ET
New Research: Key Drivers of Growth for The Chemours, Superior Industries International, Caleres, G1 THERAPEUTICS, Vitamin Shoppe, and Ocular Therapeutix — Factors of Influence, Major Initiatives and
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Chemours Company (NYSE:CC), Superior Industries International, Inc....
Apr 02, 2019 07:00 am ET
G1 Therapeutics to Present at the 18th Annual Needham Healthcare Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced Chief Executive Officer Mark Velleca, M.D., Ph.D., will present a company overview at the 18th Annual Needham Healthcare Conference. The presentation will take...
Mar 04, 2019 07:00 am ET
G1 Therapeutics to Present at Cowen and Company 39th Annual Healthcare Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced Chief Executive Officer Mark Velleca, M.D., Ph.D., will present a company overview at the Cowen and Company 39th Annual Healthcare Conference. The presentation...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.